Ivan Twose-Alvarez

Toledo, CM, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 115 publications

Diagnosis of clonal mast cell disease in patients with anaphylaxis.

Diagnosis of clonal mast cell disease in patients with anaphylaxis.

Journal: The journal of allergy and clinical immunology. In practice

Published: April 21, 2026

Avapritinib achieves long-term disease control with favorable safety in patients with indolent systemic mastocytosis over 3 years.

Avapritinib achieves long-term disease control with favorable safety in patients with indolent systemic mastocytosis over 3 years.

Journal: The Journal of allergy and clinical immunology

Published: December 16, 2025

The REMA Score Revisited: An Optimized Algorithm for Early Prediction of Clonal Mast Cell Disease.

The REMA Score Revisited: An Optimized Algorithm for Early Prediction of Clonal Mast Cell Disease.

Journal: Allergy

Published: October 19, 2025

Management of Mastocytosis and Mast Cell Activation in Children.

Management of Mastocytosis and Mast Cell Activation in Children.

Journal: The journal of allergy and clinical immunology. In practice

Published: October 02, 2025

KIT mutation and AHN-associated oncogenic profiles in systemic mastocytosis with an associated hematological neoplasm.

KIT mutation and AHN-associated oncogenic profiles in systemic mastocytosis with an associated hematological neoplasm.

Journal: Blood advances

Published: September 10, 2025

KIT mutation and AHN-associated oncogenic profiles in systemic mastocytosis with an associated hematological neoplasm.

KIT mutation and AHN-associated oncogenic profiles in systemic mastocytosis with an associated hematological neoplasm.

Journal: Blood advances

Published: September 10, 2025

Hymenoptera anaphylaxis and mast cell activation disorders.

Hymenoptera anaphylaxis and mast cell activation disorders.

Journal: Current opinion in allergy and clinical immunology

Published: July 11, 2025

Efficacy and safety of avapritinib in advanced systemic mastocytosis: 4-year follow-up of the PATHFINDER study.

Efficacy and safety of avapritinib in advanced systemic mastocytosis: 4-year follow-up of the PATHFINDER study.

Journal: Blood advances

Published: June 20, 2025

Efficacy and safety of avapritinib in advanced systemic mastocytosis: 4-year follow-up of the PATHFINDER study.

Efficacy and safety of avapritinib in advanced systemic mastocytosis: 4-year follow-up of the PATHFINDER study.

Journal: Blood advances

Published: June 20, 2025

Anaphylaxis events in the PIONEER study of avapritinib in indolent systemic mastocytosis.

Anaphylaxis events in the PIONEER study of avapritinib in indolent systemic mastocytosis.

Journal: The World Allergy Organization journal

Published: May 29, 2025

Patient-Reported Outcomes and Provider Perceptions of Systemic Mastocytosis: Results From the PRISM Study.

Patient-Reported Outcomes and Provider Perceptions of Systemic Mastocytosis: Results From the PRISM Study.

Journal: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology

Published: April 25, 2025

Prevalence of KIT D816V in anaphylaxis or systemic mast cell activation.

Prevalence of KIT D816V in anaphylaxis or systemic mast cell activation.

Journal: The Journal of allergy and clinical immunology

Published: April 21, 2025

Showing 1-12 of 115

Last Updated: 09/26/2026